![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 30, 23281-23286, July 28, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From
Received for publication, December 21, 1999, and in revised form, April 13, 2000
We have previously shown that hypertonicity
stimulates cyclooxygenase-2 (COX-2) expression in cultured medullary
epithelial cells. The aims of the present study were (i) to examine the
role of cytoplasmic signaling through MAPK pathways in tonicity
regulation of COX-2 expression in collecting duct cells and (ii) to
assess the possible contribution of COX-2 to the survival of inner
medullary collecting duct (IMCD) cells under hypertonic conditions. In
mIMCD-K2 cells, a cell line derived from mouse IMCDs, hypertonicity
induced a marked increase in COX-2 protein expression. The stimulation was reduced significantly by inhibition of MEK1 (PD-98059, 5-50 µM) and p38 (SB-203580, 5-100 µM)
and was almost abolished by the combination of the two compounds. To
study the role of JNK in tonicity-stimulated COX-2 expression, IMCD-3
cell lines stably transfected with dominant-negative mutants of three
JNKs (JNK-1, -2, and -3) were used. Hypertonicity-stimulated COX-2
protein expression was significantly reduced in dominant-negative
JNK-2-expressing cells and was unchanged in dominant-negative JNK-1-
and JNK-3-expressing cells compared with controls. The reduction of
COX-2 expression was associated with greatly reduced viability of
dominant-negative JNK-2-expressing cells during hypertonicity
treatment.
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) (2-8 µM), an inhibitor of Src kinases, reduced the
tonicity-stimulated COX-2 expression in a dose-dependent
manner, whereas PP3, an inactive analog of PP2, had no effect.
Inhibition of COX-2 activity by NS-398 (30-90 µM) and
SC-58236 (10-20 µM) significantly reduced viability of
mIMCD-K2 cells subjected to prolonged hypertonic treatment. We conclude
that 1) all three members of the MAPK family (ERK, JNK-2, and p38) as
well as Src kinases are required for tonicity-stimulated COX-2
expression in mouse collecting duct cells and that 2) COX-2 may play a
role in cell survival of medullary cells under hypertonic conditions.
A large body of experimental work has demonstrated that
accumulation of compatible osmolytes such as sorbitol, inositol,
taurine, glycerophosphorylcholine, and betaine is essential for
survival of medullary cells under hypertonic conditions (1). Recent studies suggest that the osmotic responsiveness of cells is a complex
process involving the participation of multiple mitogen-activated protein kinases (MAPKs).1 It
has been shown in yeast that high osmolality glycerol (Hog1) kinase,
the yeast homolog of p38 kinase, is activated by hypertonicity and is
responsible for the induction of glycerol-3-phosphate dehydrogenase, the enzyme essential for production of glycerol, the major organic osmolyte in yeast (2, 3). Furthermore, a yeast Hog1 deletion mutant is
lethal under hypertonic conditions, and the lethality is rescued by
overexpression of mammalian wild-type p38 (4) or c-Jun
NH2-terminal kinase (JNK) (5). The evidence supports a
critical role of MAPKs in the regulation of osmolyte accumulation during osmotic stress in yeast. Several studies indicate that mammalian
MAPKs may have a similar function in tonicity responses as their yeast
homologs. Several groups have demonstrated that all three members of
the MAPK family, p38, JNK, and the extracellular signal-regulated
kinase (ERK), can be activated in mammalian cells by hypertonicity
(6-9). In a study by Wojtaszek et al. (10), hypertonicity
was shown to selectively activate JNK-2, but not JNK-1, in mouse
medullary epithelial cells, and a dominant-negative mutant of JNK-2
reduced cell viability under hypertonic conditions independent of
inositol accumulation.
Cyclooxygenase (COX) plays a key role in regulation of prostaglandin
synthesis and is probably rate-limiting under some circumstances. Two
isoforms of cyclooxygenase have been identified by molecular approaches, a constitutive form (COX-1) and an inducible form (COX-2).
The two forms share similar enzymatic properties, but differ markedly
with respect to cellular expression pattern and regulation. In general,
COX-1 is expressed constitutively in a wide variety of tissues and is
considered to have "housekeeping" functions. COX-2 is more
restricted in its expression and can be dramatically induced in
inflammatory cells by cytokines as well as by mitogenic factors (11).
Inducibility is also a characteristic of COX-2 expression in a variety
of organ systems, including the kidney. Previous studies from our
laboratory have shown that chronic salt loading (12) or water
deprivation (13) induced COX-2, but not COX-1, expression in the renal
medulla in vivo and that hypertonicity induced COX-2, but
not COX-1, expression in collecting duct cell lines in
vitro. The present study examined the signaling pathway
responsible for the tonicity-stimulated COX-2 expression in inner
medullary collecting duct (IMCD) cell lines. We demonstrate that
inhibition of any one of the three MAPKs p38, ERK, and JNK-2 by
SB-203580, PD-58059, and a dominant-negative mutant, respectively, significantly suppressed hypertonicity-stimulated COX-2 expression in
cultured medullary epithelial cells. Blockade of JNK-1 or JNK-3 was
without effect, however. Inhibition of the Src kinase family by PP2
also suppressed hypertonicity-stimulated COX-2 expression. We further
show that COX-2 inhibitors induced a marked reduction of cell viability
of medullary epithelial cells under hypertonic conditions.
Materials--
Cell culture media and serum were from Life
Technologies, Inc. PD-98059 was obtained from New England Biolabs Inc.
(Beverly, MA), and SB-203580 from Upstate Biotechnology, Inc.
(Lake Placid, NY). Tyrphostin-23 and -51 and MTT tetrazolium salt were
from Sigma. Anti-murine COX-2 polyclonal antibody and NS-398 were
obtained from Cayman Chemical Co., Inc. (Ann Arbor MI). SC-58236 was a generous gift from Monsanto.
Cell Culture--
mIMCD-K2 is an established inner medullary
collecting duct cell line that was provided by Dr. Bruce Stanton (14).
The cells were routinely propagated in Opti-MEM supplemented with 10%
fetal bovine serum, 100 units/ml penicillin, and 100 µg/ml
streptomycin. JNK dominant-negative mutant cells were generated from
the mouse IMCD-3 cell line provided by Dr. Steve Gullans (10). IMCD-3 cells were propagated in a 1:1 mixture of Dulbecco's modified Eagle's
medium and Ham's F-12 nutrient mixture supplemented with 10% fetal
bovine serum, 100 units/ml penicillin, and 100 µg/ml streptomycin.
Generation of Stable JNK-1, -2, and -3 Transfectants--
Generation of the three stable JNK
dominant-negative cell lines has been described previously (10).
Experiments were performed in two independent clones of each stable
cell line.
Western Blotting--
Cells were lysed and sonicated in 30 mM Tris-Cl, pH 7.5, and 100 µM
phenylmethylsulfonyl fluoride. Protein concentrations were determined
by Coomassie reagent. 100 µg of protein from the whole cell lysate
were separated by SDS-polyacrylamide gel electrophoresis and
transferred onto nitrocellulose membranes. The blots were blocked
overnight with 5% nonfat dry milk in Tris-buffered saline, followed by
incubation for 1 h with rabbit anti-murine COX-2 polyclonal antiserum at a dilution of 1:1000. After washing with Tris-buffered saline, blots were incubated with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody and visualized with ECL kits (Amersham Pharmacia Biotech).
MTT Assay--
The assay was performed as described previously
(15). Briefly, mIMCD-K2 cells grown in six-well plates were washed with phosphate-buffered saline and incubated at 37 °C with 1 ml of MTT (1 mg/ml) for 2 h. After replacing the MTT solution with 1 ml of
1-propanol, cells were gently shaken at room temperature for 10 min.
Absorbance at 540 and 690 nm was read in 20-µl samples in a
spectrophotometer, and results are expressed as the difference between
specific absorbance at 540 nm and background absorbance at 690 nm.
PGE2 Enzyme Immunoassay--
PGE2 in the
culture medium was measured with an enzyme immunoassay kit (Cayman
Chemical Co., Inc.). The assay was performed according to the
manufacturer's instructions. Briefly, 25 or 50 µl of the medium,
along with a serial dilution of PGE2 standard samples, were
mixed with appropriate amounts of acetylcholinesterase-labeled tracer
and PGE2 antiserum and incubated at room temperature for 18 h. After the wells were emptied and rinsed with wash buffer, 200 µl of Ellman's reagent containing substrate for
acetylcholinesterase were added. The enzyme reaction was carried out on
a slow shaker at room temperature for 1 h. The plates were read at
415 nm, and the results were analyzed by DeltaSOFT II software.
Statistical Analysis--
Values represent means ± S.D.
Statistical analysis was performed by Student's t test,
with p < 0.05 being considered statistically significant.
Effect of MAPK Inhibitors and NS-398 on Hypertonicity-stimulated
PGE2 Release from Cultured mIMCD-K2 Cells--
Confluent
mIMCD-K2 cells were pretreated with SB-203580, PD-98059, or NS-398 for
30 min, followed by hypertonic treatment for 16 h.
PGE2 release was determined by enzyme immunoassay. As we
have shown previously (13), hypertonic treatment induced a 50-fold
increase in PGE2 release from mIMCD-K2 cells. The
stimulation was significantly suppressed by all three compounds (Fig.
1). Among these inhibitors, SB-203580
exhibited the most potent effect, and it also abolished basal
PGE2 release.
Effect of p38 and MEK1 Inhibitors on Hypertonicity-stimulated COX-2
Expression--
Consistent with our previous observations (13),
hypertonicity induced a marked increase in COX-2 protein expression in
mIMCD-K2 cells. As shown in Figs. 2 and
3, this stimulation was partially suppressed by both SB-203580 and PD-98059, commonly used inhibitors of
p38 kinase and MEK1 (16, 17). Combined treatment with the two
inhibitors almost completely abolished the stimulatory effect of
hypertonicity (Fig. 3C). It has been reported that SB-203580 can inhibit cyclooxygenase activity (18). To rule out the possibility that the effect of SB-203580 might be a secondary consequence of COX
inhibition, we examined the effect of SC-58236, a COX-2-specific inhibitor, on COX-2 expression in mIMCD-K2 cells. In contrast to the
inhibitory effect of SB-203580 on COX-2 expression, SC-58236 stimulated
COX-2 expression (Fig. 2D).
Effect of Overexpression of Dominant-negative Mutants of JNK
Isoforms on Hypertonicity-stimulated COX-2 Expression--
To study
the role of JNK in hypertonicity-stimulated COX-2 expression, we used
IMCD-3 cell lines stably transfected with dominant-negative mutants of
JNK-1, -2, or -3 (10). Densitometric values of COX-2 protein from two
independent clones of each cell line were averaged. Hypertonicity
significantly induced COX-2 expression in neomycin control and JNK-1
and JNK-3 dominant-negative cell lines. In contrast, stimulation was
significantly blunted in the two clones of the JNK-2 dominant-negative
cell line (Fig. 4). COX-2 protein in
JNK-2 dominant-negative cells in the basal state was also reduced
compared with neomycin control and JNK-1 dominant-negative cell lines. The reduction of COX-2 expression was associated with greatly reduced
viability of cells expressing dominant-negative JNK-2 during the
hypertonic treatment as determined by MTT assay (Fig. 5).
Effect of Tyrosine Kinase Inhibitors on Hypertonicity-stimulated
COX-2 Expression--
Tyrphostin-23 and -51, specific inhibitors of
epidermal growth factor receptor tyrosine kinase, had no obvious
effect on tonicity-stimulated COX-2 expression (Fig.
6C). In contrast, PP2, an
inhibitor of non-receptor Src tyrosine kinases (2-8 µM),
significantly reduced tonicity-stimulated COX-2 expression in a
dose-dependent manner, whereas PP3, an inactive analog of
PP2, had no effect (Fig. 6A).
Effect of COX-2 Inhibitors on Viability of mIMCD-K2 Cells--
To
test a potential function of COX-2 as a cytoprotective agent during an
osmotic challenge, we examined the effect of COX-2 inhibitors on cell
viability of mIMCD-K2 cells exposed to hypertonic medium. mIMCD-K2
cells were grown for 7 days in hypertonic or isotonic medium in the
presence or absence of the COX-2-specific inhibitors NS-398 and
SC-58236. To achieve maximal osmotic stress, the initial medium
osmolarity of 600 mosmol/liter was increased over 3 days to 750 mosmol/liter by adding NaCl and was maintained at this level until day
7. Cell viability was assessed by morphological analysis (Fig.
7) and MTT assay (Fig.
8). Under hypertonic conditions, both
NS-398 (30-90 µM) and SC-58236 (10-20 µM)
significantly reduced cell viability in a time- and
dose-dependent manner. These effects became apparent at 3 days and were maximal at 7 days of drug treatment. At this time, NS-398
(90 µM) and SC-58236 (20 µM) reduced the optical density from 0.095 ± 0.027 to 0.059 ± 0.020 (n = 4, p < 0.05) and 0.035 ± 0.008 (n = 4, p < 0.01), respectively.
In contrast, neither drug had any obvious effect on cell viability under isotonic conditions.
The study demonstrates that inhibition of any one of the three
MAPKs p38, ERK, and JNK-2 significantly suppresses
hypertonicity-stimulated COX-2 expression and that the simultaneous
inhibition of the p38 and ERK pathways almost completely prevents COX-2
induction. In addition, the selective non-receptor tyrosine kinase
inhibitor PP2 suppresses the stimulation of COX-2 by hypertonicity,
whereas inhibition of epidermal growth factor receptor tyrosine kinase has no effect. These findings indicate that activation of multiple MAPKs as well as non-receptor tyrosine kinases participates in the
cytoplasmic signaling pathways that mediate the effect of hypertonicity
on COX-2 expression in medullary epithelial cells. Finally, our data
show that COX-2 inhibitors cause a marked reduction of cell viability
of medullary epithelial cells under hypertonic, but not isotonic,
conditions, supporting the notion of a cytoprotective function of COX-2
in the cellular response to hypertonicity.
An impressive body of work has established that cells adapt to
environmental hypertonicity by inducing a cluster of
osmolyte-associated genes, including aldose reductase and the
transporters for betaine, taurine, and myo-inositol. The
expressed proteins are responsible for the synthesis or uptake of
compatible organic osmolytes (1, 19). The complexity of the
intracellular mechanisms mediating the response to environmental
osmotic changes is revealed by recent observations that hypertonicity
activates multiple protein kinases, including all three MAPKs p38, JNK,
and ERK, as well as tyrosine kinases, including epidermal growth factor
receptor tyrosine kinase (20), and that activation of these kinases is
associated with the induction of immediate early genes, including
Egr-1 and c-fos (21, 22). It is well established
that the p38 homolog Hog1 regulates the production of the major yeast
osmolyte glycerol, a prerequisite for yeast growth under hypertonic
conditions. Conflicting observations exist regarding the association of
MAPKs with osmolyte accumulation in mammals (23, 24). There is
increasing evidence that the function of MAPKs in the osmotic response
in mammalian cells is not limited to regulating the accumulation of
compatible osmolytes. In support of this notion is the finding that p38
and ERK play a role in hypotonicity-stimulated HSP-70 expression (16). In addition, a study by Wojtaszek et al. (10) has
demonstrated that a dominant-negative mutant of JNK-2 reduced cell
viability without affecting inositol uptake. It appears that MAPKs are
involved in the osmotic response in mammalian cells through more
diverse mechanisms than in yeast and that the activation of multiple
MAPK pathways may affect both osmolyte-dependent and
-independent mechanisms. The major contribution of the present study is
the demonstration that COX-2 is a target of MAPKs in mammalian cells
during osmotic perturbations and that it exerts a cytoprotective
function during hypertonic stress. The MAPK/COX-2 relationship appears
to be a novel pathway in the overall osmotic response of mammalian
cells that is probably dissociated from osmolyte accumulation.
Using pharmacological blockade of p38 and ERK pathways and
dominant-negative mutants of various forms of JNK (JNK-1, -2, and -3),
we have demonstrated that interference with each of the three MAPK
pathways significantly suppresses hypertonicity-stimulated COX-2
expression and that combined inhibition of p38 and ERK virtually completely abolishes the stimulation. This is consistent with the
finding that MAPK inhibitors suppress hypertonicity-stimulated PGE2 release. The inhibition of COX activity by SB-203580
is particularly potent in that it abolishes even basal PGE2
release. This is likely due to an inhibitory effect of SB-203580 on
COX-2 expression and COX activity (18). Our findings suggest that all
three MAPK pathways are required for the induction of COX-2 by
hypertonicity and that the different MAPK pathways act in an additive
fashion. Simultaneous activation of more than one MAPK pathway is also required for the stimulation of COX-2 expression by both cytokines (17)
and ceramide (25). Taken together, these findings suggest that
cooperative action of multiple MAPKs mediates the activation of COX-2
in response to various external stimuli. The detailed mechanism for
MAPK-mediated activation of COX-2 expression is not clear. It is
possible that the three MAPKs p38, ERK, and JNK-2 phosphorylate
different transcription factors that form a complex and that bind to
osmolality-responsive elements in the COX-2 promoter region. The
specificity of the signaling pathway for a given stimulus is likely
determined by differences in upstream mediators. However, the existence
of various isoforms of MAPKs could also contribute to the specificity
of the signaling. In support of this notion are the findings that
hypertonicity selectively activates JNK-2, but not the other isoforms
of JNK, and that hypertonicity-stimulated COX-2 is reduced only in
JNK-2-expressing cells, but not in dominant-negative JNK-1- and
JNK-3-expressing cells.
It has been noted that tyrosine kinases are involved in the signaling
mechanism for both cytokine- and mitogen-stimulated COX-2 expression in
pancreatic islet and mesangial cells (26, 27) and that hyperosmolality
activates tyrosine kinases in various cell culture systems (20, 28). We
have previously shown that genistein significantly inhibited
hypertonicity-stimulated COX-2 expression in mIMCD-K2 cells (13).
Although it has been observed previously that hypertonicity can
activate epidermal growth factor receptor tyrosine kinase in HeLa
cells, blockade of this kinase with its specific inhibitors
tyrphostin-23 and -51 had no effect in medullary epithelial cells. In
contrast, PP2, an inhibitor of the non-receptor-linked tyrosine kinase
of the Src family, significantly suppressed hypertonicity-stimulated
COX-2 expression. This finding suggests that hypertonicity-stimulated
COX-2 expression is associated with Src kinase activation. Concomitant
activation of Src and MAPK has been shown previously to regulate COX-2
expression in breast cells (29, 30). We speculate that Src kinases in renal medullary cells may be activated by osmotic stress and that they
may function as osmosensors that transduce the signal to MAPKs, leading
to activation of COX-2 expression.
Our present results show that the COX-2 inhibitors NS-398 and SC-58236
reduced cell viability of medullary epithelial cells during exposure to
hypertonicity, but had no obvious effect under isotonic conditions,
supporting the cytoprotective function of COX-2 in medullary cells.
This finding is consistent with a number of previous observations on
the growth-promoting and cytoprotective function of COX-2. For example,
it has been shown that inhibition of COX-2 induces cell death in
cultured medullary interstitial cells and colon cancer cells (31, 32)
and that overexpression of COX-2 is protective against apoptosis in
intestinal endothelial cells (33). The mechanism of the cytoprotective
action of COX-2 is not clear. Recent studies have demonstrated that
15-deoxy- In summary, our data show that inhibition of one of the three MAPKs
p38, ERK, and JNK-2 significantly suppresses hypertonicity-stimulated COX-2 expression in cultured medullary epithelial cells. Selective inhibition of the Src kinase family by PP2 also suppresses the hypertonicity-stimulated COX-2 expression. Furthermore, COX-2 inhibitors induce a marked reduction of cell viability of medullary epithelial cells under hypertonic conditions. We conclude that hypertonicity stimulates COX-2 expression through activation of multiple MAPKs as well as Src kinases and that the induction of COX-2
may exert a specific cytoprotective function in the overall osmotic
response of medullary epithelial cells.
*
This work was supported by NIDDK Grants DK-37448, DK-39255,
and DK-40042 from the National Institutes of Health and in part by the
General Clinical Research Center at the University of Michigan, funded
by United States Public Health Service Grant M01RR00042 from the
National Center for Research Resources, National Institutes of Health.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: NIDDK, NIH, Bldg.
31, Rm. 9A17, 31 Center Dr., MSC 2560, Bethesda, MD 20892. Tel.: 301-496-6325; Fax: 301-402-4874; E-mail:
BriggsJ@hq.niddk.nih.gov.
Published, JBC Papers in Press, May 1, 2000, DOI 10.1074/jbc.M910237199
The abbreviations used are:
MAPKs, mitogen-activated protein kinases;
JNK, c-Jun NH2-terminal
kinase;
ERK, extracellular signal-regulated kinase;
COX, cyclooxygenase;
IMCD, inner medullary collecting duct;
PP2, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide;
PGE2, prostaglandin E2;
MEK, MAPK/ERK
kinase.
MAPK Mediation of Hypertonicity-stimulated Cyclooxygenase-2
Expression in Renal Medullary Collecting Duct Cells*
,
,
, and
¶
NIDDK, National Institutes of Health, Bethesda,
Maryland 20892 and the § Department of Internal Medicine,
University of Colorado, Denver, Colorado 80262
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (17K):
[in a new window]
Fig. 1.
Effect of MAPK inhibitors and a COX-2
inhibitor on hypertonicity-stimulated PGE2 release.
Confluent mIMCD-K2 cells were pretreated with 15 µM
SB-203580, PD-98059, or NS-398 for 30 min, followed by exposure to
hypertonicity (550 mosmol/liter by addition of NaCl) for 16 h. The
medium was collected and assayed for PGE2 using enzyme
immunoassay. Bars indicate means ± S.D.
mosm/l, milliosmoles per liter.

View larger version (29K):
[in a new window]
Fig. 2.
Effect of the p38 kinase inhibitor SB-203580
and of the COX-2 inhibitor SC-58236 on hypertonicity-stimulated COX-2
protein expression in cultured mIMCD-K2 cells. COX-2 protein from
40 µg of whole cell lysates was analyzed by Western blotting using an
anti-COX-2 polyclonal antibody. A, effect of SB-203580 at
the indicated concentrations on COX-2 expression in confluent mIMCD-K2
cells exposed to hypertonic conditions (550 mosmol/liter by addition of
NaCl to isotonic medium) for 16 h; B, densitometric
analysis of band intensities shown in A; C, COX-2
expression in confluent mIMCD-K2 cells exposed to hypertonicity (550 mosmol/liter) for the indicated periods of time in the presence of
vehicle or 15 µM SB-203580; D, effect of
SC-58236 at the indicated doses on COX-2 expression in mIMCD -K2 cells
exposed to hypertonicity for 16 h. mosm/l, milliosmoles
per liter.

View larger version (24K):
[in a new window]
Fig. 3.
Effect of the MEK1 inhibitor PD-98059 alone
and in combination with SB-203580 on hypertonicity-stimulated COX-2
protein expression in cultured mIMCD-K2 cells. A,
effect of PD-98059 at the indicated concentrations on COX-2 expression
in mIMCD-K2 cells subjected to hypertonic treatment (550 mosmol/liter
by addition of NaCl to isotonic medium) for 16 h; B,
densitometric analysis of the bands shown in A;
C, effect of PD-98059 or SB-203580 alone or in combination
at the indicated concentrations on COX-2 expression in mIMCD-K2 cells
exposed to hypertonicity for 16 h; D, densitometric
analysis of the bands shown in C. mosm/l, milliosmoles per liter.

View larger version (12K):
[in a new window]
Fig. 4.
Effect of overexpression of dominant-negative
mutants of JNKs on hypertonicity-stimulated COX-2 protein expression in
IMCD-3 cells. Stable cell lines were generated by
retrovirus-mediated transfection with dominant-negative
(D/N) mutants of JNK-1, -2, and -3 and with neomycin
(Neo) control vector. Each stable cell line contains two
independent clones. Cells were treated with isotonic or hypertonic (550 mosmol/liter) medium for 16 h, and COX-2 expression was determined
by Western blotting. Shown are the results from the densitometric
analysis of COX-2 protein. The values from two independent clones for
each cell line are pooled.

View larger version (15K):
[in a new window]
Fig. 5.
Cell viability of various stable JNK cell
lines following exposure to hyperosmolarity. The stable IMCD cells
were exposed to hyperosmolarity (600 mosmol/liter by addition of NaCl
to the medium) for 24 h. Cell viability was assessed by MTT assay.
The values from two independent clones for each cell line are pooled.
Values are means ± S.D.

View larger version (37K):
[in a new window]
Fig. 6.
Effect of PP2 on hypertonicity-stimulated
COX-2 protein expression in mIMCD-K2 cells. A,
immunoblot of COX-2 showing the effects of PP2 and PP3 at the indicated
concentrations; B, corresponding densitometric analysis of
the bands shown in A; C, immunoblot showing the
effects of tyrphostin-23 and -51 (10 µM) on
hypertonicity-stimulated COX-2 expression in mIMCD-K2 cells.
mosm/l, milliosmoles per liter.

View larger version (147K):
[in a new window]
Fig. 7.
Morphological analysis of COX-2
inhibitor-induced cell death in mIMCD-K2 cells. Confluent mIMCD-K2
cells were treated with isotonic or hypertonic medium in the presence
or absence of NS-398 (30-90 µM) or SC-58236 (10-20
µM) for 7 days. To achieve maximal osmotic stress, the
initial medium osmolarity of 600 mosmol/liter was increased over 3 days
to 750 mosmol/liter by adding NaCl and was maintained at this level
until day 7. Shown are mIMCD-K2 cells grown at the indicated days
following hypertonic treatment in the presence of 20 µM
SC-58236 or 90 µM NS-398. Cells treated with an
equivalent amount of solvent (Me2SO) served as controls (at
day 7).

View larger version (16K):
[in a new window]
Fig. 8.
Analysis of cell viability by MTT assay.
Confluent mIMCD-K2 cells were treated with isotonic or hypertonic
medium in the presence or absence of 90 µM NS-398 or 20 µM SC-58236 for 7 days. MTT assay was performed as
described under "Experimental Procedures." Values are means ± S.D.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
12-14-prostaglandin J2 is a
natural ligand for the
-isoform of the peroxisomal
proliferator-activated receptor, an observation that, together with the
presence of COX-2 in the nuclear envelope, establishes the existence of
a nuclear pathway for the action of prostaglandins (34, 35). Studies
from our (36) and other (37) laboratories have demonstrated predominant
expression of peroxisomal proliferator-activated receptor-
in the
renal medulla, where COX-2 is abundantly expressed. These findings
raise the possibility that COX-2 products may exert their
cytoprotective role through nuclear receptors.
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Burg, MB.
(1995)
Am. J. Physiol.
268,
F983-F996
2.
Ruis, H.,
and Schüller, C.
(1995)
Bioessays
17,
959-965
3.
Albertyn, J.,
Hohmann, S.,
Thevelein, J. M.,
and Prior, B. A.
(1994)
Mol. Cell. Biol.
14,
4135-4144
4.
Han, J.,
Lee, J. D.,
Bibbs, L.,
and Ulevitch, R. J.
(1994)
Science
265,
808-811
5.
Galcheva-Gargova, Z.,
Dérijard, B.,
Wu, I. H.,
and Davis, R. J.
(1994)
Science
265,
806-808
6.
Moriguchi, T.,
Kawasaki, H.,
Matsuda, S.,
Gotoh, Y.,
and Nishida, E.
(1995)
J. Biol. Chem.
270,
12969-12972
7.
Itoh, T.,
Yamauchi, A.,
Miyai, A.,
Yokoyama, K.,
Kamada, T.,
Ueda, N.,
and Fujiwara, Y.
(1994)
J. Clin. Invest.
93,
2387-2392
8.
Terada, Y.,
Tomita, K.,
Homma, M. K.,
Nonoguchi, H.,
Yang, T.,
Yamada, T.,
Yuasa, Y.,
Krebs, E. G.,
Sasaki, S.,
and Marumo, F.
(1994)
J. Biol. Chem.
269,
31296-31301
9.
Berl, T.,
Siriwardana, G.,
Ao, L. L.,
Butterfield, L. M.,
and Heasley, L. E.
(1997)
Am. J. Physiol.
41,
F305-F311
10.
Wojtaszek, P. A.,
Heasley, L. E.,
Siriwardana, G.,
and Berl, T.
(1998)
J. Biol. Chem.
273,
800-804
11.
Hershman, H. R.
(1996)
Biochim. Biophys. Acta
1299,
125-140
12.
Yang, T.,
Singh, I.,
Pham, H.,
Sun, D.,
Smart, A.,
Schnermann, J. B.,
and Briggs, J. P.
(1998)
Am. J. Physiol.
274,
F481-F489
13.
Yang, T.,
Schnermann, J. B.,
and Briggs, J. P.
(1999)
Am. J. Physiol.
46,
F1-F9
14.
Kizer, Z. L.,
Lewis, B.,
and Stanton, B. A.
(1995)
Am. J. Physiol.
37,
F347-F355
15.
Denizot, F.,
and Lang, R.
(1986)
J. Immunol. Methods
89,
271-277
16.
Sheikh-Hamad, D.,
Di Mari, J.,
Suki, W. N.,
Safirstein, R.,
Watts, B. A., III,
and Rouse, D.
(1998)
J. Biol. Chem.
273,
1832-1837
17.
Guan, Z.,
Buckman, S. Y.,
Miller, B. W.,
Springer, L. D.,
and Morrison, A. R.
(1998)
J. Biol. Chem.
273,
28670-28676
18.
Borsch-Haubold, A. G.,
Pasquet, S.,
and Watson, S.
(1998)
J. Biol. Chem.
273,
28766-28772
19.
Burg, M. B.,
Kwon, E. D.,
and Kultz, D.
(1997)
Annu. Rev. Physiol.
59,
437-455
20.
Rosette, C.,
and Karin, M.
(1996)
Science
274,
1194-1197
21.
Zhang, Z.,
and Cohen, D. M.
(1997)
Am. J. Physiol.
273,
F837-F842
22.
Cohen, D. M.,
and Gullans, S. R.
(1993)
Am. J. Physiol.
264,
F593-F600
23.
Kultz, D.,
Garcia-Perez, A.,
Ferraris, J. D.,
and Burg, M. B.
(1997)
J. Biol. Chem.
272,
13165-13170
24.
Nadkarni, V.,
Gabbay, K. H.,
Bohren, K. M.,
and Sheikh-Hamad, D.
(1999)
J. Biol. Chem.
274,
20185-20190
25.
Subbaramaiah, K.,
Chung, W. J.,
and Dannenberg, A. J.
(1998)
J. Biol. Chem.
273,
32943-32949
26.
Corbett, J. A.,
Kwon, G.,
Marino, M. H.,
Rodi, C. P.,
Sullivan, P. M.,
Turk, J.,
and McDaniel, M. L.
(1996)
Am. J. Physiol.
270,
C1581-C1587
27.
Coroneos, E. J.,
Kester, M.,
Maclouf, J.,
Thomas, P.,
and Dunn, M. J.
(1997)
J. Am. Soc. Nephrol.
8,
1080-1090
28.
Szaszi, K.,
Buday, L.,
and Kapus, A.
(1997)
J. Biol. Chem.
272,
16670-16678
29.
Subbaramaiah, K.,
Telang, N.,
Ramonetti, J. T.,
Araki, R.,
DeVito, B.,
Weksler, B. B.,
and Dannenberg, A. J.
(1996)
Cancer Res.
56,
4424-4429
30.
Lee, R. J.,
Albanese, C.,
Stenger, R. J.,
Watanabe, G.,
Inghirami, G.,
Haines, G. K., III,
Webster, M.,
Muller, W. J.,
Brugge, J. S.,
Davis, R. J.,
and Pestell, R. G.
(1999)
J. Biol. Chem.
274,
7341-7350
31.
Hao, C. M.,
Kömhoff, M.,
Guan, Y.,
Redha, R.,
and Breyer, M. D.
(1999)
Am. J. Physiol.
277,
F352-F359
32.
Sheng, H.,
Shao, J.,
Kirkland, S. C.,
Isakson, P.,
Coffey, R. J.,
Morrow, J.,
Beauchamp, R. D.,
and DuBois, R. N.
(1997)
J. Clin. Invest.
99,
2254-2259
33.
Tsujii, M.,
and DuBois, R. N.
(1995)
Cell
83,
493-501
34.
Forman, B. M.,
Tontonoz, P.,
Chen, J.,
Brun, R. P.,
Spiegelman, B. M.,
and Evan, R. M.
(1995)
Cell
83,
803-812
35.
Spencer, A. G.,
Woods, J. W.,
Arakawa, T.,
Singer, I. I.,
and Smith, W. L.
(1998)
J. Biol. Chem.
273,
9886-9893
36.
Yang, T.,
Michele, D. E.,
Park, J.,
Smart, A. M.,
Lin, Z.,
Brosius, F. C., III,
Schnermann, J. B.,
and Briggs, J. P.
(1999)
Am. J. Physiol.
277,
F966-F973
37.
Guan, Y.,
Zhang, Y.,
Davis, L.,
and Breyer, M. D.
(1997)
Am. J. Physiol.
273,
F1013-F1022
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
F. Hanner, R. Chambrey, S. Bourgeois, E. Meer, I. Mucsi, L. Rosivall, G. E. Shull, J. N. Lorenz, D. Eladari, and J. Peti-Peterdi Increased renal renin content in mice lacking the Na+/H+ exchanger NHE2 Am J Physiol Renal Physiol, April 1, 2008; 294(4): F937 - F944. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kuper, H. Bartels, M.-L. Fraek, F. X. Beck, and W. Neuhofer Ectodomain shedding of pro-TGF-{alpha} is required for COX-2 induction and cell survival in renal medullary cells exposed to osmotic stress Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1971 - C1982. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-Y. Chai, Y.-C. Huang, W.-C. Hung, W.-Y. Kang, and W.-T. Chen Arsenic salt-induced DNA damage and expression of mutant p53 and COX-2 proteins in SV-40 immortalized human uroepithelial cells Mutagenesis, November 1, 2007; 22(6): 403 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Liu, Y. Yang, C. Gu, Y. Yue, K. K. Wu, J. Wu, and Y. Zhu Spike protein of SARS-CoV stimulates cyclooxygenase-2 expression via both calcium-dependent and calcium-independent protein kinase C pathways FASEB J, May 1, 2007; 21(7): 1586 - 1596. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Zhang, J. Li, K. Wu, W. Ouyang, J. Ding, Z.-g. Liu, M. Costa, and C. Huang JNK1, but not JNK2, is required for COX-2 induction by nickel compounds Carcinogenesis, April 1, 2007; 28(4): 883 - 891. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Naor, H. N. Jabbour, M. Naidich, A. J. Pawson, K. Morgan, S. Battersby, M. R. Millar, P. Brown, and R. P. Millar Reciprocal Cross Talk between Gonadotropin-Releasing Hormone (GnRH) and Prostaglandin Receptors Regulates GnRH Receptor Expression and Differential Gonadotropin Secretion Mol. Endocrinol., February 1, 2007; 21(2): 524 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Zhang, M.-H. Wang, Z. Dong, and T. Yang Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor Am J Physiol Renal Physiol, December 1, 2006; 291(6): F1323 - F1331. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yang, A. Zhang, A. Pasumarthy, L. Zhang, Z. Warnock, and J. B. Schnermann Nitric oxide stimulates COX-2 expression in cultured collecting duct cells through MAP kinases and superoxide but not cGMP Am J Physiol Renal Physiol, October 1, 2006; 291(4): F891 - F895. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhou, P. Bouyer, and W. F. Boron Role of a tyrosine kinase in the CO2-induced stimulation of HCO3- reabsorption by rabbit S2 proximal tubules Am J Physiol Renal Physiol, August 1, 2006; 291(2): F358 - F367. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Grishin, J. Wang, D. A. Potoka, D. J. Hackam, J. S. Upperman, P. Boyle, R. Zamora, and H. R. Ford Lipopolysaccharide Induces Cyclooxygenase-2 in Intestinal Epithelium via a Noncanonical p38 MAPK Pathway J. Immunol., January 1, 2006; 176(1): 580 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Yang, A. Zhang, M. Honeggar, D. E. Kohan, D. Mizel, K. Sanders, J. R. Hoidal, J. P. Briggs, and J. B. Schnermann Hypertonic Induction of COX-2 in Collecting Duct Cells by Reactive Oxygen Species of Mitochondrial Origin J. Biol. Chem., October 14, 2005; 280(41): 34966 - 34973. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Sun, N. G. Carlson, A. C. Hemmert, and B. K. Kishore P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function Am J Physiol Renal Physiol, September 1, 2005; 289(3): F585 - F592. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Hasler, M. Vinciguerra, A. Vandewalle, P.-Y. Martin, and E. Feraille Dual Effects of Hypertonicity on Aquaporin-2 Expression in Cultured Renal Collecting Duct Principal Cells J. Am. Soc. Nephrol., June 1, 2005; 16(6): 1571 - 1582. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, M. Zhao, R. Rao, H. Inoue, and C.-M. Hao C/EBP{beta} and Its Binding Element Are Required for NF{kappa}B-induced COX2 Expression Following Hypertonic Stress J. Biol. Chem., April 22, 2005; 280(16): 16354 - 16359. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Cohen SRC family kinases in cell volume regulation Am J Physiol Cell Physiol, March 1, 2005; 288(3): C483 - C493. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Umenishi, S. Yoshihara, T. Narikiyo, and R. W. Schrier Modulation of Hypertonicity-Induced Aquaporin-1 by Sodium Chloride, Urea, Betaine, and Heat Shock in Murine Renal Medullary Cells J. Am. Soc. Nephrol., March 1, 2005; 16(3): 600 - 607. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Kim, Y.-H. Kim, K.-J. Shin, Y.-S. Oh, C. S. Lee, K.-O. Kang, S. H. Ryu, and P.-G. Suh 2,2',4,6,6'-Pentachlorobiphenyl-Induced Apoptosis Is Limited by Cyclooxygenase-2 Induction Toxicol. Sci., February 1, 2005; 83(2): 397 - 404. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. W. Slice, T. Chiu, and E. Rozengurt Angiotensin II and Epidermal Growth Factor Induce Cyclooxygenase-2 Expression in Intestinal Epithelial Cells through Small GTPases Using Distinct Signaling Pathways J. Biol. Chem., January 14, 2005; 280(2): 1582 - 1593. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Capasso, C. J. Rivard, and T. Berl Synthesis of the Na-K-ATPase {gamma}-subunit is regulated at both the transcriptional and translational levels in IMCD3 cells Am J Physiol Renal Physiol, January 1, 2005; 288(1): F76 - F81. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Sheikh-Hamad and M. C. Gustin MAP kinases and the adaptive response to hypertonicity: functional preservation from yeast to mammals Am J Physiol Renal Physiol, December 1, 2004; 287(6): F1102 - F1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhao, W. Tian, C. Tai, and D. M. Cohen Hypertonic induction of COX-2 expression in renal medullary epithelial cells requires transactivation of the EGFR Am J Physiol Renal Physiol, August 1, 2003; 285(2): F281 - F288. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Capasso, C. J. Rivard, L. M. Enomoto, and T. Berl Chloride, not sodium, stimulates expression of the {gamma} subunit of Na/K-ATPase and activates JNK in response to hypertonicity in mouse IMCD3 cells PNAS, May 27, 2003; 100(11): 6428 - 6433. [Abstract] |